期刊档案 · RESPIRATORY SYSTEM
Therapeutic Advances in Respiratory Disease
ISSN 1753-4658 · eISSN 1753-4666 · SAGE Publications Ltd · ENGLAND
Therapeutic Advances in Respiratory Disease 中科院 医学 3区（2025 年升级版），影响因子 3.14，完全开放获取，APC 约 2,650 美元，投稿社区反馈审稿约 15 周，官网公布录用率 18%，2025 年发文 105 篇，SCIE、Scopus 收录。
研究范围
研究范围与定位
Therapeutic Advances in Respiratory Disease 由 SAGE Publications Ltd 出版，属中科院医学大类（2025 升级版3区）。按 OpenAlex 近年发文统计，该刊主要发表 Chronic Obstructive Pulmonary Disease (COPD) Research、Asthma and respiratory diseases、Respiratory Support and Mechanisms 等主题的论文，这 3 个主题约占 38.3%，主导子领域为 Pulmonary and Respiratory Medicine。（根据 OpenAlex 主题统计与中科院分区数据生成）
Journal HighlightsLaunched in 2007.Gold open access journal – all articles are made freely available online immediately upon publication.Rigorous peer review.Listed in PubMed and indexed in Science Citation Index Expanded (SCIE), Scopus, ProQuest and MEDLINE.Therapeutic Advances in Respiratory Disease is a peer-reviewed open access journal which focuses on pioneering efforts and innovative studies across all areas of respiratory disease. Please see the aims and scope tab for further information.This journal is a member of the Committee on Publication Ethics (COPE).This journal flipped to open access on September 1, 2017.Diversity, Equity and Inclusion StatementTherapeutic Advances in Respiratory Disease promotes inclusive, open science that reflects the disciplinary, human, and geographic diversity of the respiratory disease community.Diversity as a core value embodies inclusiveness, mutual respect, and multiple perspectives.We welcome editors, editorial board members, peer reviewers and authors from all backgrounds, cultures, ethnicities, nationalities, races, religions, sexes, sexual orientations, gender identities, mental or physical (dis)abilities, ages, career stages, socioeconomic status or any other individual status.We are committed to continually improving our editorial and review processes whilst playing our part in eradicating bias and inequality in all forms.Submission informationSubmit your manuscript today at http://mc.manuscriptcentral.com/tar.Please see the submission guidelines tab for more information on how to submit your article to the journal.Open access informationUnsolicited manuscripts submitted to Therapeutic Advances in Respiratory Disease are subject to an article processing charge (APC) of $3,200 USD. The APC for a Plain Language Summary is $5,500 USD.These articles will be published under a Creative Commons licence and will be made openly available.The APC is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here.ContactPlease direct any queries to respiratory@sagepub.co.uk.
摘自期刊官网 Aims & Scope
研究方向（LetPub）：RESPIRATORY SYSTEM
主编 Nazia Chaudhuri出版商官网
编委会国家分布：中国大陆 10 位（约 6%）；主要国家 美国 37、意大利 25、英国 22、土耳其 11、中国 10（共 162 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Chronic Obstructive Pulmonary Disease (COPD) ResearchMedicine17.9%
- Asthma and respiratory diseasesMedicine12.7%
- Respiratory Support and MechanismsMedicine7.7%
- Respiratory and Cough-Related ResearchMedicine7.1%
- Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisMedicine6.8%
- Cystic Fibrosis Research AdvancesMedicine4.8%
- Pulmonary Hypertension Research and TreatmentsMedicine4.6%
- Inhalation and Respiratory Drug DeliveryMedicine4.6%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）医学 3 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 3 区 |
| 小类 | 呼吸系统RESPIRATORY SYSTEM | 3 区 |
Top 期刊：否综述期刊：否
《新锐期刊分区表》（ 2026年3月发布）医学 3 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 3 区 |
| 小类 | 呼吸系统RESPIRATORY SYSTEM | 3 区 |
Top 期刊：否综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）医学 3 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 3 区 |
| 小类 | 呼吸系统RESPIRATORY SYSTEM | 4 区 |
Top 期刊：否综述期刊：否
数据库收录
SCIEScopusDOAJLetPub
国际期刊预警名单：各版本均未列入LetPub
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子
- 3.14LetPub ·
- 影响因子（出版商公布）
- 3.2出版商官网 ·
- 五年影响因子（出版商公布）
- 3.5出版商官网 ·
- CiteScore 2026-06
- 5.1LetPub ·
- SJR 2026-06
- 1.01LetPub ·
- SNIP 2026-06
- 1.11LetPub ·
- h-index
- 32LetPub ·
- h-index
- 67OpenAlex ·
- i10-index
- 542OpenAlex ·
- 两年平均被引
- 3.35OpenAlex ·
- 自引率
- 3.1%LetPub ·
- Gold OA 文章占比
- 100%LetPub ·
发文规模
- 年文章数
- 97LetPub ·
- 年发文量（出版商公布）
- 3出版商官网 ·
逐年发文量 OpenAlex 统计 · 累计 1,046 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 97 | 97 | 23 |
| 2025 | 105 | 105 | 431 |
| 2024 | 95 | 95 | 541 |
| 2023 | 79 | 79 | 837 |
| 2022 | 67 | 67 | 1,221 |
| 2021 | 49 | 49 | 1,100 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
- 平均审稿速度（社区反馈）
- 15 WeeksLetPub ·
- 录用率（出版商公布）
- 18%出版商官网 ·
- 投稿到首次决定
- 4 天出版商官网 ·
- 接收到发表
- 27 天出版商官网 ·
- 投稿到发表（期刊自报）
- 约 15 周DOAJ ·
- 评审方式
- 开放同行评审DOAJ
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
完全开放获取DOAJ
所有文章开放获取，通常向作者收取文章处理费（APC）。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | USD 2,650 | 有 | CC BY、CC BY-NC | |
| OpenAlex | USD 2,650 | — | — | |
| LetPub | USD 2,650 | 有 | — | |
| 出版商官网 | USD 3,200 / USD 5,500 | — | — |
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点1 项，摘自作者指南
- 参考文献格式
- Vancouver 格式
接收的文章类型9 种
- original articleView our Special Collections currently accepting submissions Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstract…未说明篇幅
- original articlesOriginal Articles.The Editors will consider clinical interventional and observational studies with clearly stated aims, well-reported methodology (including mai…未说明篇幅
- original research articleView our Special Collections currently accepting submissions Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstract…未说明篇幅
- perspectiveView our Special Collections currently accepting submissions Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstract…未说明篇幅
- reviewView our Special Collections currently accepting submissions Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstract…未说明篇幅
- review articleView our Special Collections currently accepting submissions Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstract…未说明篇幅
- review articlesReview Articles. These manuscripts are usually commissioned by the Editors but unsolicited reviews will be considered.未说明篇幅
- scoping reviewsScoping Reviews– These reviews assess the scope of available literature on a topic through comprehensive synthesis.未说明篇幅
- systematic reviewView our Special Collections currently accepting submissions Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstract…未说明篇幅
官网政策摘录作者资格、数据可用性、出版伦理、开放获取、同行评审、查重、预印本、试验注册 / 报告规范
- 作者资格 Author contributions
该期刊采用CRediT（贡献者角色分类法，包含14种角色）描述每位作者对工作的具体贡献，作者需在提交过程中列出各作者的贡献，并在提交稿件的致谢部分之后加入“作者贡献”标题。 模型中文摘要
As part of our commitment to ensuring an ethical, transparent and fair peer review and publication process, this journal has adopted CRediT (Contributor Roles Taxonomy). CRediT is a high-level taxonomy, including 14 roles, which is used to describe each author’s individual contributions to the work. You will be asked to list the contribution of each author as part of the submission process. Please…
原文 ↗出版商官网 ·- 数据可用性 Data availability
该期刊鼓励作者在符合伦理和法律要求的前提下，将研究数据存入相关公共数据仓库，附上链接数据的数据可用性声明（如无法共享则说明原因），并在研究中引用该数据。 模型中文摘要
The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages. Subject to appropriate ethical and legal considerations, authors are encouraged to: Share your research data in a relevant public data repository Include a data ava…
原文 ↗出版商官网 ·- 出版伦理 Ethical considerations
作者须在指定标题下提供伦理批准声明（即使方法部分已包含），如无需伦理批准也须明确说明；报告涉及人类参与者、人类数据或人体组织的研究时，须注明相关伦理委员会或机构审查委员会批准或豁免，并提供委员会全名、所属机构及批准编号。 模型中文摘要
Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved th…
原文 ↗出版商官网 ·- 开放获取 Publishing fees and open access
该期刊为开放获取、同行评审期刊，所有被接受的文章在出版后立即免费在线发布，采用知识共享许可并永久在线托管；同行评审后被接受的文章须支付一次性文章处理费（APC），由资助者、机构或作者承担，提交稿件不收费，标准APC为3200美元。 模型中文摘要
Therapeutic Advances in Respiratory Disease is an open access, peer-reviewed journal. All accepted articles are made freely available online immediately upon publication, are published under a Creative Commons license, and hosted online in perpetuity. If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable to cover the cost of publi…
原文 ↗出版商官网 ·- 同行评审 Peer review policy
该期刊采用单匿名同行评审（审稿人姓名对作者保密），稿件先经初步评估，不符合指南要求的稿件将被退回修改，超出范围或不合适的稿件可能未经同行评审即被直接拒稿，通过初评后进入同行评审。 模型中文摘要
The following summary describes the peer review process for this journal: Identity transparency: Single-anonymized Reviewer interacts with: Editor Review information published: None Your manuscript will undergo an initial evaluation. If it does not conform to the requirements laid out in these guidelines, it will be returned to you for amendments prior to peer review. Manuscripts may be desk rejec…
原文 ↗出版商官网 ·- 查重 Plagiarism
该期刊和Sage严肃对待版权侵权、抄袭及其他违反出版最佳实践的问题，作者应阅读Sage完整的抄袭政策及可能采取的措施。 模型中文摘要
The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.
原文 ↗出版商官网 ·- 预印本 Preprints
该期刊考虑已在预印本服务器发布的稿件，作者提交时须在指定字段输入预印本DOI，并建议在提交时告知期刊编辑部；稿件在同行评审期间不应在预印本服务器发布更新版本。 模型中文摘要
The journal will consider submissions of manuscripts that have been posted on preprint servers. Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission. Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed…
原文 ↗出版商官网 ·- 试验注册 / 报告规范 Clinical trial registration
该期刊遵循ICMJE要求，临床试验须在首次招募参与者之前或当时在WHO认可的公共试验注册机构注册，作为考虑发表的条件，且试验注册机构名称、URL和注册号必须列在摘要末尾。 模型中文摘要
The journal conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- SAGE Publications Ltd
- 出版国家或地区
- ENGLAND
- 出版语言
- English
- ISSN
- 1753-4658
- 电子版 ISSN
- 1753-4666
- 官方链接
- 期刊主页 ↗DOAJ
- 投稿系统 ↗LetPub
- 作者指南 ↗LetPub
- Aims & Scope ↗LetPub
- 专刊 / 特刊征稿 ↗出版商官网
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗LetPub
- 编委会 ↗LetPub
- 查重政策 ↗DOAJ
常见问题
关于 Therapeutic Advances in Respiratory Disease 的常见问题
Therapeutic Advances in Respiratory Disease 是中科院几区期刊？
2025 年升级版分区表中，Therapeutic Advances in Respiratory Disease 为医学 3区，小类 呼吸系统 3 区。2026 年新锐版分区表中为医学 3区。不同版本与大小类分区不能混用。
Therapeutic Advances in Respiratory Disease 的影响因子是多少？
LetPub 汇总的最新公布影响因子为 3.14，CiteScore 为 5.1，h-index 为 67。
Therapeutic Advances in Respiratory Disease 的审稿周期多长？
投稿社区反馈的平均审稿速度为约 15 周；期刊官网公布的录用率为 18%。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Therapeutic Advances in Respiratory Disease 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 162 位编委中，中国大陆 10 位（约 6%）；人数最多的国家是 美国（37 位）、意大利（25 位）、英国（22 位）。统计按编委会页面列出的机构国家计，仅供参考。
Therapeutic Advances in Respiratory Disease 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Therapeutic Advances in Respiratory Disease 被 SCIE、Scopus、DOAJ 收录。
Therapeutic Advances in Respiratory Disease 是开放获取期刊吗？版面费多少？
Therapeutic Advances in Respiratory Disease 为完全开放获取。APC 约 2,650 美元。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex、DOAJ；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-25 归档）。最近更新：。